Table 3 Optimal combination strategies under different annual PCSCI
From: Modeling optimal combination of breast and cervical cancer screening strategies in China
PCSCI threshold (USD) | Optimal combination strategies | |
|---|---|---|
Breast cancer | Cervical cancer | |
18.33 | Biennial CBE&BUS | Quinquennial TCT |
18.80 | Biennial BUS&MAM | Quinquennial HPV |
20.68 | Annual BUS&MAM | Quinquennial HPV |
22.56 | Annual CBE|BUS | Quinquennial HPV |
24.44 | Annual CBE|BUS | Triennial HPV |
26.32 | Annual CBE|BUS | Biennial HPV |
28.20 | Annual MAM | Quinquennial HPV |
30.08 | Annual CBE|BUS|MAM | Quinquennial HPV |
31.96 | Annual CBE|BUS|MAM | Triennial HPV |
33.84 | Annual CBE|BUS|MAM | Biennial TCT triage after primary HPV screening |
35.72 | Annual CBE|BUS|MAM | Biennial HPV |
37.60 | Annual CBE|BUS|MAM | Biennial TCT|HPV |
39.48 | Annual CBE|BUS|MAM | Biennial TCT|HPV |